Xeomin (incobotulinumtoxina)

pCPA File Number: 21621

Negotiation Status:

Concluded without agreement

Indication(s):

Chronic Sialorrhea associated with neurological disorders

Sponsor/Manufacturer:

Merz Therapeutics Canada

CDA-AMC Project Number:

SR0678-000

pCPA Engagement Letter Issued:

2022-01-28

Negotiation Process Concluded:

2022-12-23